A systematic management algorithm for handling immune therapy–mediated diarrhea and colitis in hospitalized patients was associated with earlier clinical remission, fewer readmissions and recurrences, and better overall survival than were seen before the process was incorporated, investigators from The University of Texas MD Anderson Cancer Center, in Houston, reported.
Checkpoint inhibitors can predispose patients with cancer to immune-mediated diarrhea and colitis (IMDC). The algorithm